A pancancer analysis of histone deacetylase 3 in human tumors.

Hao Chen, Fan Xu, Anqi Qin, Shuai Guo, Ge Zhang, Bo Yu, Quanhui Zheng
Author Information
  1. Hao Chen: Hebei Key Laboratory for Chronic Diseases, School of Basic Medical Sciences, North China University of Science and Technology, Tangshan, China.
  2. Fan Xu: Hebei Key Laboratory for Chronic Diseases, School of Basic Medical Sciences, North China University of Science and Technology, Tangshan, China.
  3. Anqi Qin: Hebei Key Laboratory for Chronic Diseases, School of Basic Medical Sciences, North China University of Science and Technology, Tangshan, China.
  4. Shuai Guo: Hebei Key Laboratory for Chronic Diseases, School of Basic Medical Sciences, North China University of Science and Technology, Tangshan, China.
  5. Ge Zhang: Hebei Key Laboratory for Chronic Diseases, School of Basic Medical Sciences, North China University of Science and Technology, Tangshan, China.
  6. Bo Yu: Department of Neurosurgery 1, Tangshan Workers' Hospital Affiliated to Hebei Medical University, Tangshan, China.
  7. Quanhui Zheng: Hebei Key Laboratory for Chronic Diseases, School of Basic Medical Sciences, North China University of Science and Technology, Tangshan, China.

Abstract

Background: Histone deacetylase 3 () is known to be an important role in various kinds of cancer, but its effect has not been examined on the pancancer level. Thus, a systematic pancancer analysis was conducted to explore its potential role in pancancer diagnosis, prognosis, and immune correlation research.
Methods: We used a series of databases including The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx) Project, The University of Alabama at Birmingham Cancer data analysis portal (UALCAN), Tumor Immune Estimation Resource (TIMER), and Search Tool for the Retrieval of Interacting Genes/Proteins (STRING), among others, to analyze the relationship between the expression of and the diagnosis and prognosis of cancer, the tumor microenvironment (TME), immune infiltration, tumor mutational burden (TMB), microsatellite instability (MSI), mismatch repair (MMR) system using various bioinformatics methods. Downstream pathways of were identified by gene set enrichment analysis (GSEA). Furthermore, the protein expression of HDAC3 in tumor tissues and normal tissues of 17 patients with gliomas was analyzed via western blotting.
Results: The expression of changed in most types of tumors, which was closely related to most tumor diagnoses and negatively related to some patients' overall survival (OS) and recurrence-free survival (RFS). The pan-cancer analysis demonstrated that it was tightly correlated to DNA methylation and RNA methylation modifications and associated with TMB and MSI. The expression level of was positively correlated with many immune checkpoint molecules and regulators and positively associated with the infiltration levels of immune cells in the TME in most tumor types. Furthermore, enrichment analysis revealed that transcriptional misregulation in cancer and RNA splicing functions were involved in the functional mechanism of -related genes. Experimental research showed that the protein expression of HDAC3 was elevated in tumor tissues of patients with glioma.
Conclusions: Through our comprehensive bioinformatics analysis, we evaluated the role of in pancancer, and our findings suggest that it may be an indicator for some cancer diagnoses and influence immune balance.

Keywords

References

  1. Nat Rev Clin Oncol. 2018 May;15(5):325-340 [PMID: 29508855]
  2. Front Cell Dev Biol. 2022 Mar 10;10:840759 [PMID: 35359455]
  3. Cancer Commun (Lond). 2021 Sep;41(9):904-920 [PMID: 34146461]
  4. Leukemia. 2017 Dec;31(12):2670-2677 [PMID: 28490812]
  5. Mol Med Rep. 2014 Oct;10(4):2045-50 [PMID: 25050565]
  6. J Immunol. 2015 Aug 15;195(4):1578-90 [PMID: 26163592]
  7. Genes Chromosomes Cancer. 2022 Jun;61(6):314-321 [PMID: 34837268]
  8. Cancer Res. 2019 Jul 15;79(14):3676-3688 [PMID: 31097476]
  9. Imeta. 2022 Jul 08;1(3):e36 [PMID: 38868713]
  10. Neurochem Res. 2016 Dec;41(12):3192-3205 [PMID: 27632183]
  11. Cell. 2012 Jul 6;150(1):12-27 [PMID: 22770212]
  12. Nat Genet. 2022 May;54(5):670-683 [PMID: 35468964]
  13. World Neurosurg. 2018 Nov;119:e145-e158 [PMID: 30053564]
  14. Front Immunol. 2020 May 07;11:784 [PMID: 32457745]
  15. Clin Epigenetics. 2018 Dec 11;10(1):153 [PMID: 30537988]
  16. Sci Rep. 2017 Jul 19;7(1):5784 [PMID: 28724935]
  17. Eur J Med Chem. 2020 Apr 15;192:112171 [PMID: 32163814]
  18. Semin Cancer Biol. 2021 Feb;69:238-248 [PMID: 31883449]
  19. OMICS. 2012 May;16(5):284-7 [PMID: 22455463]
  20. Neuropathol Appl Neurobiol. 2019 Aug;45(5):441-458 [PMID: 30548945]
  21. Int J Surg. 2010;8(3):194-8 [PMID: 20139036]
  22. Clin Exp Med. 2018 Feb;18(1):1-14 [PMID: 28752221]
  23. J Med Chem. 2023 Sep 14;66(17):12033-12058 [PMID: 37660352]
  24. EMBO Mol Med. 2013 Mar;5(3):366-83 [PMID: 23381944]
  25. Front Mol Biosci. 2021 Sep 01;8:720020 [PMID: 34540896]
  26. Oncoimmunology. 2017 Aug 11;6(11):e1363139 [PMID: 29147628]
  27. Cancer Cell. 2019 Apr 15;35(4):677-691.e10 [PMID: 30991027]
  28. Nat Rev Mol Cell Biol. 2017 Jan;18(1):31-42 [PMID: 27808276]
  29. BMC Clin Pathol. 2014 Mar 13;14(1):10 [PMID: 24624923]
  30. EMBO J. 2020 Oct 15;39(20):e104514 [PMID: 32964498]
  31. Cancer Gene Ther. 2021 Feb;28(1-2):141-155 [PMID: 32655129]
  32. Mol Carcinog. 2023 Jun;62(6):754-770 [PMID: 36920044]
  33. Bull Cancer. 2019 Feb;106(2):105-113 [PMID: 30342749]
  34. Ann Oncol. 2019 Jan 1;30(1):44-56 [PMID: 30395155]
  35. Nat Rev Cancer. 2012 Mar 15;12(4):298-306 [PMID: 22419253]
  36. Adv Clin Exp Med. 2018 Mar;27(3):305-311 [PMID: 29558042]
  37. Sci Adv. 2023 Mar 15;9(11):eadd3243 [PMID: 36930718]
  38. Proc Natl Acad Sci U S A. 2021 Jul 13;118(28): [PMID: 34244427]
  39. Nat Rev Cancer. 2020 Nov;20(11):662-680 [PMID: 32753728]
  40. Med Sci Monit. 2018 Apr 22;24:2456-2464 [PMID: 29680858]
  41. Cancer. 2021 Aug 15;127(16):3029-3030 [PMID: 34086348]
  42. Neoplasia. 2022 Mar;25:18-27 [PMID: 35078134]
  43. Wiley Interdiscip Rev RNA. 2013 Jul-Aug;4(4):397-422 [PMID: 23681756]
  44. J Exp Clin Cancer Res. 2019 Jun 13;38(1):255 [PMID: 31196207]
  45. Cancer Immunol Res. 2023 May 3;11(5):657-673 [PMID: 36898011]
  46. Tumour Biol. 2010 Oct;31(5):533-9 [PMID: 20563766]
  47. Cancer J. 2007 Jan-Feb;13(1):23-9 [PMID: 17464243]
  48. J Med Internet Res. 2021 Jul 26;23(7):e27633 [PMID: 34309564]
  49. Sci Rep. 2015 Mar 20;5:9087 [PMID: 25791281]
  50. Lancet Oncol. 2019 Jun;20(6):806-815 [PMID: 31036468]
  51. Biochim Biophys Acta Rev Cancer. 2021 Dec;1876(2):188609 [PMID: 34375716]

Word Cloud

Similar Articles

Cited By